Abstract:Abstract Background The COVID-19 pandemic has shown the importance of fast and sensitive PCR testing to identify SARS-CoV-2 (SC2) infected patients. Identifying infected individuals with a fast sample to answer test provides the opportunity to limit the spread of the virus and prescribe antimicrobial treatment in the same visit. Additionally, the post pandemic world has seen simultaneous outbreaks of RSV, influenza, and SC2, the so-called tridemic. These higher risk respiratory viruses can appear against a background of lower risk viruses such as rhinovirus, adenovirus, enterovirus, other corona viruses, and bacterial infections that present with similar symptoms and make triage challenging. Fast turnaround molecular testing along with multiplex detection of all key pathogens associated with flu-like symptoms is important for timely selection of treatment, counseling to contain the spread of disease, and provide public health officials information on prevalence of outbreaks. AMDI is developing a cloud-based, ultrafast, fully automated POC molecular technology that enables detection of up to 32 microbial targets in less than 10 min from sample to answer. A 15-second extraction-free hyperbaric heating (HBH) step is performed on the input swab sample to release nucleic acid and neutralize PCR inhibitors in the sample in seconds. The sample is directly transferred without dilution to a chamber where it mixes with dry RT-PCR reagents and then is dispatched to eight thin (<250 μm thick) PCR reaction cuvettes where rapid heat transfer can occur. This is followed by thermocycling on an instrument designed to achieve 10 sec per cycle and detect four fluorescent signals per cuvette. This study first evaluates the HBH method against nucleic acid purification assays using SC2 positive clinical samples. Next, a preliminary LoD on the AMDI system (HBH and fast thermocycling) was performed using inactivated SC2 and RSV whole organism in a nasal swab matrix. Methods To evaluate HBH as a sample prep method, 12 known SC2 positive remnant clinical samples in VTM or saline were diluted 1:1 with AMDI collection buffer, treated by HBH, tested by RT-PCR on QuantStudioTM and compared with the Roche LIAT. A preliminary SC2 and RSV LoD on the full AMDI system was determined by spiking dilutions of inactivated viruses into pooled nasal swab matrix, followed by treatment with HBH, and testing by RT-PCR using the ultra-fast thermocycler. Results In clinical sample testing HBH shows equal or greater sensitivity than LIAT, even for high Ct samples. HBH followed by RT-PCR detected 12/12 (100% sensitivity) samples while Roche LIAT detected 11/12 (92% sensitivity). When HBH is coupled with AMDI ultra-fast PCR thermocycling technology, an SC2 preliminary LoD of 500 copies/mL and an RSV preliminary LoD of 250 copies/mL was obtained in <9 min including a 60 second RT step. Conclusion HBH is an efficient and effective sample prep method and when coupled with ultrafast thermocycling provides sensitive PCR results in 10 minutes sample to answer.

Real-world performance of a single-use, analyser-free, molecular point-of-care test for COVID-19 used in the emergency department: Results of a prospective trial (ED-POC)

Clinical analysis on diagnostic accuracy of Bosch Vivalytic SARS-CoV-2 point-of-care test and evaluation of cycle threshold at admission for COVID-19 risk assessment

Effects of Different SARS-CoV-2 Testing Strategies in the Emergency Department on Length of Stay and Clinical Outcomes: A Randomised Controlled Trial

Clinical performance evaluation of SARS-CoV-2 rapid antigen testing in point of care usage in comparison to RT-qPCR

Evaluation of the diagnostic accuracy of two point-of-care tests for COVID-19 when used in symptomatic patients in community settings in the UK primary care COVID diagnostic accuracy platform trial (RAPTOR-C19)

Evaluation of the analytical performance of the 15-minute point-of-care DASH™ SARS-CoV-2 RT-qPCR test

Rapid Development and Validation of a Novel Laboratory-Derived Test for the Detection of SARS-CoV-2

Evaluation of a smartphone‐operated point‐of‐care device using loop‐mediated isothermal amplification technology for rapid and remote detection of SARS‐CoV‐2

Evaluation of a near-patient SARS-CoV-2 novel rapid diagnostic platform

Usability and performance of the MicroGEM Sal6830, an RT-PCR saliva-based point-of-care platform to detect SARS-CoV-2 in primary healthcare settings with non-laboratory trained operators.

A-376 Development of a 10-Minute Sample to Answer RT-PCR Respiratory Panel Performed on Point of Care (POC)

Analytical Evaluation of Visby Medical RT-PCR Portable Device for Rapid Detection of SARS-CoV-2

Evaluation of the feasibility and efficacy of point-of-care antibody tests for biomarker guided management of COVID-19

Comparative Performance of a New SARS-CoV-2 Rapid Detection System

Performance of the Flash10 COVID-19 point-of-care molecular test

Point-of-care testing for COVID-19: a simple two-step molecular diagnostic development and validation during the SARS-CoV-2 pandemic

Is point-of-care testing feasible and safe in care homes in England? An exploratory usability and accuracy evaluation of a point-of-care polymerase chain reaction test for SARS-CoV-2

Rapid Quantitative Point-Of-Care Diagnostic Test for Post COVID-19 Vaccination Antibody Monitoring

Recent advances and clinical application in point‐of‐care testing of SARS‐CoV‐2

Evaluation of Serological SARS-CoV-2 Lateral Flow Assays for Rapid Point of Care Testing

Lessons learned: drive-through COVID-19 clinic testing during an adaptive epidemic response and a point-of-care test assessment of a computer-read rapid lateral flow immunoassay with fluorescence-based detection